Agile Therapeutics, Inc. (AGRX)

Market Cap	3.09M
Revenue (ttm)	19.59M
Net Income (ttm)	-12.69M
Shares Out	6.86M
EPS (ttm)	-6.38
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	72,919
Open	0.428
Previous Close	0.430
Day's Range	0.428 - 0.486
52-Week Range	0.200 - 6.714
Beta	1.40
Analysts	Buy
Price Target	12.00 (+2,566.67%)
Earnings Date	May 9, 2024

About AGRX

Agile Therapeutics, Inc., a women's healthcare company, engages in the research, development, and commercialization of prescription contraceptive products for women in the United States. It offers Twirla, a once-weekly prescription combination hormonal contraceptive patch. The company is also developing a pipeline of Twirla line extensions and other products, including AG200-15 Extended Regimen (ER), a regimen that allows a woman to have four episodes of withdrawal bleeding per year; AG200-15 smaller patch (SmP), which is a regimen designed to ...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• IPO Date: May 23, 2014
• Employees: 19
• Stock Exchange: OTCMKTS
• Ticker Symbol: AGRX

Financial Performance

In 2023, AGRX's revenue was $19.59 million, an increase of 80.02% compared to the previous year's $10.88 million. Losses were -$14.47 million, -43.08% less than in 2022.

Analyst Forecast

According to 2 analysts, the average rating for AGRX stock is "Buy." The 12-month stock price forecast is $12.0, which is an increase of 2,566.67% from the latest price.

Price Target

$12.0

(2,566.67% upside)

Analyst Consensus: Buy